Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 plus IBI305 in advanced solid tumors
NCT07124793Phase 2Not yet recruiting
- Sponsor
- Innovent Biologics
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363 in non-small cell lung cancer (NSCLC), ovarian cancer, sponsored by Innovent Biologics. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
IBI363
03
Conditions
non-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT07124793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07124793.